Source-grounded facts extracted from LifeMD, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
LifeMD, Inc. reported the first quarter ended March 31, 2026 results: revenue $50.2 million. Guidance reaffirmed.
“2026. A copy of the press release is furnished herewith as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- LifeMD Reports First Quarter 2026 Results ● First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company’s guidance. ● Gross margin increased approximately 420 basis points to 88%, versus”
LifeMD, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $46.9 million. Guidance initiated.
“Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.”
LifeMD, Inc. reported the year ended December 31, 2025 results: revenue $194.1 million. Guidance initiated.
“Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million.”
LifeMD, Inc. entered into Credit Agreement with Citizens Bank, N.A. valued at $30 million (effective 2026-01-02).
“On January 2, 2026, LifeMD, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A. (the “Lender”), which provides for a senior secured revolving credit facility in an aggregate outstanding amount not exceeding $30 million (the “Credit Facility”)”
LifeMD, Inc. incurred revolving credit of $30 million with Citizens Bank, N.A. at Term SOFR plus 1.50% to 2.25% or Alternate Base Rate plus 0.50% to 1.25% maturing January 2, 2029.
“On January 2, 2026, LifeMD, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A. (the “Lender”), which provides for a senior secured revolving credit facility in an aggregate outstanding amount not exceeding $30 million (the “Credit Facility”) to support potential corporate development and/or shareholder value creation initiatives. The Credit Facility may be increased in the aggregate principal amount of up to $20 million on the terms and subject to the conditions described in the Credit Agreement. In connection with the Credit Agreement, among other things, the Company issued a revolving loan note to the Lender for any loans that may be made under the Credit Facility. Additionally, among other things, the Company and its subsidiaries entered into a pledge and security agreement and a guarantee agreement to provide credit support for the Credit Facility. The Credit Facility matures on January 2, 2029. The terms of the Credit Facility pr”
LifeMD, Inc. completed a disposition involving Lion Buyer, LLC for up to $52.0 million (closed 2025-11-04).
“aggregate purchase price paid at close and 53.8% ($28.0 million) subject to future performance targets, for an aggregate purchase consideration paid to the Sellers of up to $52.0 million: ● 46.2% of the aggregate purchase price consists of a cash payment equal to the base purchase price of $24.0 million, subject to adjustments for net working capital, cash,”
LifeMD, Inc. engaged PricewaterhouseCoopers LLP as its auditor.
“On August 18, 2025, the Company, with the approval of the Audit Committee of the Company’s Board of Directors, appointed PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm for the year ending December 31, 2025.”
LifeMD, Inc. dismissed CBIZ CPAs P.C. as its auditor.
“Dismissal of Independent Registered Public Accounting Firm On August 15, 2025, LifeMD, Inc. (the “Company”), with the approval of the Audit Committee of the Company’s Board of Directors, dismissed CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm.”
LifeMD, Inc. engaged CBIZ CPAs P.C. as its auditor.
“On April 24, 2025 the Company and with the approval of the Audit Committee of the Company’s Board of Directors, engaged CBIZ CPAs P.C. as the Company’s independent registered public accounting firm.”
Marcum LLP resigned as auditor of LifeMD, Inc..
“On April 24, 2025 Marcum LLP (“Marcum”), which served as the independent registered public accounting firm of LifeMD, Inc. (the “Company”, “we”, “our”) since 2022, informed the Company that Marcum resigned as the Company’s independent registered public accounting firm.”
Naveen Bhatia resigned as Member of the Board of Directors at LifeMD, Inc..
“Effective October 25, 2024, Naveen Bhatia voluntarily resigned from his position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).”
Calum MacRae was appointed as Member of the Board of Directors at LifeMD, Inc..
“On April 26, 2024, Calum MacRae was appointed to the Board of Directors.”
Bertrand Velge resigned as member of the board of directors at LifeMD, Inc..
“Effective November 8, 2023, Bertrand Velge voluntarily resigned from his position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).”
Alex Mironov resigned as President at LifeMD, Inc..
“On July 28, 2023, Alex Mironov voluntarily resigned from his position as President of LifeMD, Inc. (the “Company”) in connection with his appointment as a Managing Director of Rothschild & Co.”
LifeMD, Inc. shareholders approved Ratification of the selection of Marcum LLP as LifeMD's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.
“Proposal 2: Votes For Votes Against Votes Abstained Broker Non-Votes 20,184,888 329,773 607,897 N/A”
LifeMD, Inc. shareholders approved Election of nine directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified at the 2023-06-16 meeting.
“Proposal 1: Director’s Name Votes For Votes Withheld Broker Non-Votes Justin Schreiber 12,845,743 1,050,026 7,226,789 Stefan Galluppi 12,844,346 1,051,423 7,226,789 Naveen Bhatia 12,847,245 1,048,524 7,226,789 Joseph DiTrolio 12,481,019 1,414,750 7,226,789 Roberto Simon 11,245,842 2,649,927 7,226,789 John Strawn, Jr. 11,254,813 2,640,956 7,226,789 Bertrand Velge 11,258,383 2,637,386 7,226,789 Robert Jindal 13,034,725 861,044 7,226,789 Joan LaRovere 13,029,312 866,457 7,226,789”
William J. Febbo was appointed as Director at LifeMD, Inc..
“On June 20, 2023, William J. Febbo was appointed to the Board of Directors.”
Stefan Galluppi resigned as Director at LifeMD, Inc..
“On June 20, 2023, Stefan Galluppi resigned from the Board of Directors of LifeMD, Inc. (the "Company") effective immediately.”
LifeMD, Inc. incurred credit facility of up to $40 million with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. at variable rate per annum equal to the greater of (i) the sum of 4.75% plus the Pr maturing October 1, 2026.
“On March 21, 2023, LifeMD, Inc. (the “Company”) entered into and closed on a Loan and Security Agreement (the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (together with Avenue Venture Opportunities Fund II, L.P., the “Lenders”), and a Supplement to the Loan Agreement (the “Supplement”), pursuant to which the Lenders made available to the Company a senior secured credit facility with an aggregate principal amount of up to $40 million (the “Credit Facility”), consisting of an initial advance of $15 million drawn by the Company on March 21, 2023 and an additional commitment to make loans of up to $5 million in the fourth quarter of 2023.”
LifeMD, Inc. entered into Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. valued at $40,000,000 (effective 2023-03-21).
“On March 21, 2023, LifeMD, Inc. (the “Company”) entered into and closed on a Loan and Security Agreement (the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (together with Avenue Venture Opportunities Fund II, L.P., the “Lenders”), and a Supplement to the Loan Agreement (the “Supplement”), pursuant to which the Lenders made available to the Company a senior secured credit facility with an aggregate principal amount of up to $40 million (the “Credit Facility”), consisting of an initial advance of $15 million drawn by the Company on March 21, 2023 and an additional commitment to make loans of up to $5 million in the fourth quarter of 2023.”
Kathleen E. Walsh resigned as Director at LifeMD, Inc..
“Effective February 9, 2023, Kathleen E. Walsh voluntarily resigned from her position as a member of the Board in connection with her appointment as the Secretary of the Executive Office of Health and Human Services for the Commonwealth of Massachusetts.”
Dr. Joan LaRovere was appointed as Director at LifeMD, Inc..
“On February 9, 2023, LifeMD, Inc. (the “Company”) appointed Dr. Joan LaRovere to the board of directors (the “Board”) of the Company.”
LifeMD, Inc. amended First Amendment to the Purchase Agreement (effective 2023-02-04).
“On February 4, 2023, the Company entered into the First Amendment to the Purchase Agreement (the "Amendment"), pursuant to which the Purchase Agreement was amended to, among other things: (i) reduce the total purchase price by $250,000 to a total of $3,670,000;”
Kathleen E. Walsh was appointed as director at LifeMD, Inc..
“On December 15, 2022, LifeMD, Inc. (the “Company”) appointed Kathleen E. Walsh to the board of directors (the “Board”) of the Company.”
Robert Jindal was appointed as director at LifeMD, Inc..
“On September 14, 2022, LifeMD, Inc. (the “Company”) appointed Robert Jindal to the board of directors (the “Board”) of the Company.”
Maria Stan was appointed as Controller and Principal Accounting Officer at LifeMD, Inc..
“Effective February 4, 2022, Maria Stan was appointed as Controller and Principal Accounting Officer of LifeMD, Inc. (the “Company”).”
Dr. Eleanor C. Mariano resigned as member of the board of directors at LifeMD, Inc..
“Director Resignation Effective November 8, 2021, Dr. Eleanor C. Mariano voluntarily resigned from her position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).”
Naveen Bhatia was appointed as Director at LifeMD, Inc..
“On September 8, 2021, the Company appointed Naveen Bhatia as a member of the Board.”
Happy Walters resigned as Director at LifeMD, Inc..
“On September 8, 2021, Happy Walters resigned from the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.